The Left Atrial Appendage (LAA) closure is a crucial procedure to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation. Boston Scientific Watchman FLX device is particularly beneficial for patients who are at an increased risk for stroke and systemic embolism, as identified by CHA2DS2-VASc scores. It’s especially valuable for those who are recommended for anticoagulation therapy but are restricted from its use by their physician.
The safety and effectiveness of the Watchman FLX device as a final solution compared to anticoagulation therapy is truly promising.
Proud to share this fascinating result from Prof. Dr. László GELLÉR and Team, Semmelweis University.
#BostonScientific #DHSHungary #DeliveringHealthcareSolutions #cardiology #innovation #medicaldevice #WatchmanFLX #LAAC
